Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Chemoradiation in Anaplastic Thyroid Cancer
NCT03211117Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Aug 2017
- Primary completion
- Feb 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in anaplastic thyroid cancer (ATC) (2 cohorts), sponsored by Mayo Clinic. Primary endpoint: Overall Survival Rate at 6 months. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT03211117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03211117.